The Global Market for qPCR and dPCR Instrumentation is Forecast to Reach US$3.9 Billion by 2020
Focus on
Quantifying Nucleic Acid Molecules Spurs Growth in the qPCR & dPCR
Instrumentation Market, According to a New Report by Global
Industry Analysts, Inc.
GIA announces the
release of a comprehensive global report on qPCR and dPCR Instrumentation. The
global market for qPCR and dPCR Instrumentation is forecast to reach US$3.9
billion by 2020, driven by continuous advancements in nucleic acid detection
and quantification and the rapidly shifting focus of molecular biology research
from cataloguing genes and mRNA towards quantifying nucleic acid molecules.
Polymerase Chain
Reaction (PCR) represents one of the fastest growing technologies in the life
sciences industry.
Growing global interest among cell biologists in subcellular visualization is
driving growth in nucleic acid detection technologies like qPCR and dPCR. The need for deeper understanding of gene expressions will continue
to benefit the qPCR and dPCR instruments and reagents market. Expanding applications in
fields ranging from pharma, biotech, food & beverage to animal feed, will
additionally spur growth in the market. The Human Genome Project and other recent advancements in
molecular diagnostics and genetics have created significant demand for qPCR and
dPCR in a wide range of markets, such as drug discovery, disease diagnosis,
life sciences research, and forensics, among others. Falling cost of nucleic
acid detection, quantification, and amplification techniques will additionally
encourage adoption of qPCR and dPCR instrumentation in research and diagnosis
in developing resource poor countries.
In
multi-factorial diseases like cancer there is an acute need for accurate and
reliable molecular diagnostic, prognostic, and predictive testing techniques. Under this
scenario, qPCR is finding new applications in tumor profiling. Digital PCR, on the other hand, is being increasingly
used in monitoring targeted drug therapies with Herceptin. The emergence of single-cell
molecular-biology is forecast to spur demand for single-cell qPCR, given the
limitation associated with conventional RNA methods in handling the cellular
heterogeneity of tissue cells. Key factors driving the growth of single-cell
molecular-biology include adoption of advanced genomic tools, development of Next-Generation
Sequencing (NGS), and the establishment of dedicated institutions. Education and Research constitutes the
largest end-use market for qPCR and dPCR instrumentation. Testing Laboratories will
however spur future growth in the market.
Quantitative PCR represents the largest product market supported by a
large installed base, and technology benefits such as affordability,
user-familiarity, and broad application possibilities. While qPCR is a
relatively mature market, dPCR represents an emerging market driven by the strong
demand for high-precision nucleic acid quantification and viral detection. The
need to improve the throughput and multiplexing capabilities of qPCR systems is
resulting in the integration of automation robotic systems, such as liquid
handling robots in pharmaceutical and government research laboratories.
As stated by the new market research report on qPCR and
dPCR Instrumentation, the United States represents the largest market
worldwide. Asia-Pacific is forecast to spearhead global growth with a CAGR of 7.2%
over the analysis period, led by the increased use of qPCR in blood donor
testing & screening and diagnosis of tropical diseases like Malaria. Other
macroeconomic factors encouraging growth in the region include increase in government
and consumer per-capita spending on healthcare, expanding healthcare needs
compounded by the medical tourism trend and the ensuing need to improve the quality
of diagnosis and treatment.
Major players covered
in the report include Agilent Technologies; Becton, Dickinson and Company;
BioFire Diagnostics Inc.; Bio-Rad Laboratories Inc.; Cepheid; Eppendorf AG;
Exiqon A/S; F. Hoffmann-La Roche Ltd.; Fluidigm Corp.; Illumina Inc.; Promega
Corp.; RainDance Technologies Inc.; Qiagen N.V.; Takara Bio Inc.; Thermo Fisher
Scientific Inc.; among others.
Comments
Post a Comment